# A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101

> **NCT05667129** · PHASE1 · COMPLETED · sponsor: **Xeno Biosciences** · enrollment: 97 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** XEN-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05667129
- **Lead sponsor:** Xeno Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-01
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05667129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05667129, "A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05667129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*